NZ630569A - Process for the purification of diaminophenothiazinium compounds - Google Patents

Process for the purification of diaminophenothiazinium compounds

Info

Publication number
NZ630569A
NZ630569A NZ630569A NZ63056914A NZ630569A NZ 630569 A NZ630569 A NZ 630569A NZ 630569 A NZ630569 A NZ 630569A NZ 63056914 A NZ63056914 A NZ 63056914A NZ 630569 A NZ630569 A NZ 630569A
Authority
NZ
New Zealand
Prior art keywords
diaminophenothiazinium
purification
azure
stabilised
protonated
Prior art date
Application number
NZ630569A
Other languages
English (en)
Inventor
Malvin Eutick
Original Assignee
Eupharma Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013903099A external-priority patent/AU2013903099A0/en
Application filed by Eupharma Pty Ltd filed Critical Eupharma Pty Ltd
Publication of NZ630569A publication Critical patent/NZ630569A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/20—[b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
NZ630569A 2013-08-15 2014-08-15 Process for the purification of diaminophenothiazinium compounds NZ630569A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2013903099A AU2013903099A0 (en) 2013-08-15 Purification method and compounds
PCT/AU2014/000807 WO2015021500A1 (en) 2013-08-15 2014-08-15 Process for the purification of diaminophenothiazinium compounds

Publications (1)

Publication Number Publication Date
NZ630569A true NZ630569A (en) 2017-06-30

Family

ID=52467850

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ630569A NZ630569A (en) 2013-08-15 2014-08-15 Process for the purification of diaminophenothiazinium compounds

Country Status (14)

Country Link
US (1) US9701648B2 (cg-RX-API-DMAC7.html)
EP (1) EP3033331B1 (cg-RX-API-DMAC7.html)
JP (1) JP6111381B2 (cg-RX-API-DMAC7.html)
KR (1) KR101741235B1 (cg-RX-API-DMAC7.html)
CN (1) CN105612148B (cg-RX-API-DMAC7.html)
BR (1) BR112016002979A8 (cg-RX-API-DMAC7.html)
CA (1) CA2920505C (cg-RX-API-DMAC7.html)
DK (1) DK3033331T3 (cg-RX-API-DMAC7.html)
IL (1) IL243937A (cg-RX-API-DMAC7.html)
MX (1) MX354492B (cg-RX-API-DMAC7.html)
NZ (1) NZ630569A (cg-RX-API-DMAC7.html)
SG (1) SG11201601003PA (cg-RX-API-DMAC7.html)
TW (1) TWI629267B (cg-RX-API-DMAC7.html)
WO (1) WO2015021500A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3375777A1 (en) * 2017-03-15 2018-09-19 MIKROCHEM spol. s.r.o. Method for preparation of 3,7-bis-(dimethylamino)-phenothiazin-5-ium chloride or bromide
CN112358475B (zh) * 2020-11-30 2022-09-06 西北师范大学 一种苯并吡喃鎓-吩噻嗪衍生物及其制备方法和应用
CN116947783B (zh) * 2022-04-19 2026-04-17 英科隆生物技术(杭州)有限公司 一种电子媒介体的提纯方法
US20250270177A1 (en) * 2022-04-19 2025-08-28 Leadway (Hk) Limited Purification method for electron mediator

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909520A (en) 1959-10-20 Process for making acylated
DE1886C (de) 1877-12-15 1877-12-15 Basf Ag Verfahren zur darstellung blauer farbstoffe aus dimethylanilin und anderen tertiaeren aromatischen monaminen
GB1293757A (en) 1968-10-22 1972-10-25 Paines & Byrne Ltd A nerve stain composition
GB0327672D0 (en) * 2003-11-28 2003-12-31 Photopharmica Ltd Developments in biologically active methylene blue derivatives (phenothiazines)
BRPI0416928A (pt) * 2003-11-28 2007-01-16 Photopharmica Ltd desenvolvimento de derivados biologicamente ativos de azul de metileno
JP5186212B2 (ja) * 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物(mtc)などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
WO2006032879A2 (en) 2004-09-23 2006-03-30 Wista Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc)
MY162313A (en) * 2006-07-11 2017-05-31 Wista Lab Ltd Methods of synthesis and/or purification of diaminophenothiazinium compounds
FR2903696B1 (fr) 2006-07-12 2011-02-11 Provence Technologies Procede de purification de composes diaminophenothiazium
KR101888713B1 (ko) * 2011-02-11 2018-08-14 위스타 레보레이토리스 리미티드 페노티아진 디아미늄 염 및 이의 용도

Also Published As

Publication number Publication date
WO2015021500A1 (en) 2015-02-19
SG11201601003PA (en) 2016-03-30
TWI629267B (zh) 2018-07-11
EP3033331A4 (en) 2017-01-18
KR101741235B1 (ko) 2017-05-29
CA2920505C (en) 2018-04-03
DK3033331T3 (da) 2018-04-30
CA2920505A1 (en) 2015-02-19
IL243937A0 (en) 2016-04-21
EP3033331A1 (en) 2016-06-22
EP3033331B1 (en) 2018-02-21
IL243937A (en) 2017-01-31
CN105612148A (zh) 2016-05-25
US20160200696A1 (en) 2016-07-14
MX2016002085A (es) 2016-06-23
MX354492B (es) 2018-03-07
BR112016002979A8 (pt) 2020-02-04
JP2016528237A (ja) 2016-09-15
AU2014306354A1 (en) 2016-02-18
US9701648B2 (en) 2017-07-11
KR20160042929A (ko) 2016-04-20
TW201527287A (zh) 2015-07-16
CN105612148B (zh) 2018-09-14
JP6111381B2 (ja) 2017-04-05

Similar Documents

Publication Publication Date Title
PH12014000179A1 (en) New pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
UA114087C2 (xx) Похідні піридину
PH12015501960A1 (en) Processes for the preparation of an apoptosis-inducing agent
AU2012219988A8 (en) Method for removing N2O and NOX from the nitric acid production process, and an installation suitable for same
MY199066A (en) Processes for producing diazabicyclooctane compounds
UA118666C2 (uk) Похідні піразолу
NZ711192A (en) Process for making benzoxazepin compounds
JO3063B1 (ar) مركب مبتكر وطرق لانتاجه
UY33325A (es) Purificación mediante adsorción de colorante caramelo
MX2014004920A (es) Nuevos derivados de pirazina.
MX2015012809A (es) Procedimiento para la elaboracion de gadofosveset trisodico monohidratado.
MX2015013589A (es) Proceso e intermediario para la preparacion de pregabalina.
EP3072587A4 (en) Catalyst for exhaust gas purification
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
EA201270237A1 (ru) Способ получения 1-бензил-3-гидроксиметил-1н-индазола и его производных и необходимые промежуточные соединения, содержащие магний
WO2014087208A3 (en) A process of preparing alcaftadine
MX2016002085A (es) Proceso para la purificacion de compuestos de diaminofenotiazinio.
MX2020004348A (es) Métodos de síntesis química de compuestos de diaminofenotiazinio que incluyen cloruro de metiltioninio (mtc).
MY191759A (en) Processes for the preparation of pyrimidinylcyclopentane compounds
EA201300792A1 (ru) Химические соединения
MX363458B (es) Nuevos derivados de tetrazolona.
IN2015DN00962A (cg-RX-API-DMAC7.html)
MY171860A (en) Method for purifying a crude pnpnh compound
WO2015004687A3 (en) Novel tricyclic compounds and process for preparation thereof
IN2013CH05982A (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 AUG 2019 BY SPRUSON + FERGUSON

Effective date: 20180801

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 AUG 2020 BY SPRUSON + FERGUSON

Effective date: 20190715

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 AUG 2021 BY SPRUSON + FERGUSON PTY LTD

Effective date: 20200715

LAPS Patent lapsed